Johnson & Johnson sued Samsung Bioepis for allegedly breaching a contract agreement over its launch of a biosimilar to ...
Johnson & Johnson said on Monday it had filed a lawsuit against Samsung Bioepis for breaching its contract agreement with the ...
Samsung Bioepis allegedly entered into an agreement with a third-party health company, allowing it to market its own private ...
Johnson & Johnson (NYSE:JNJ) is suing Samsung Bioepis for breach of contract related to the launch of a biosimilar of J&J's ...
Johnson & Johnson filed a lawsuit against Samsung Bioepis for allegedly breaching their agreement over the launch of ...
As biosimilar versions of a big-selling Johnson & Johnson medicine reach the U.S. market, the health care giant accused one ...
Yonhap News English on MSN15h
Samsung Bioepis launches autoimmune disease treatment in U.S.Pyzchiva, a treatment for plaque psoriasis, Crohn's disease, active psoriatic arthritis and ulcerative colitis, is Samsung ...
Projections for Brazilian chicken exports this year will likely be revised upward as numerous outbreaks of avian influenza ...
Pharmalittle: We’re reading about Zepbound price and dose changes, compounders suing FDA, and more
Eli Lilly will offer more doses of its obesity drug Zepbound in vials and lower the prices of the doses it already sells ...
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Key biosimilar value driver contributes to Sandoz global growth strategy and moves company closer to becoming #1 in biosimilars ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback